DataMeds AI, Inc. (MEDS) · Insider trading
What DataMeds AI's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
No director, officer or large holder of DataMeds AI reported buying or selling at the market price in the last two years. What they did report is below.
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Patel PrashantDirector, Chief Executive Officer | Option exercise X | +100,000 | 0.01 | 282,365 | Form 4 |
| 2026-06-22 | Ajjarapu Surendra KDirector | Option exercise X | +100,000 | 0.01 | 257,645 | Form 4 |
| 2026-03-31 | Patel PrashantDirector, Chief Executive Officer | Grant or award A | +5,000,000 | 0.20 | 9,118,247 | Form 4/A |
| 2026-03-31 | Ajjarapu Surendra KDirector | Grant or award A | +5,000,000 | 0.20 | 7,882,247 | Form 4/A |
| 2025-07-02 | Peterson Michael LDirector | Grant or award A | −200,000 | 0.90 | 200,000 | Form 4 |
| 2025-03-21 | Shanahan Rebecca MDirector | Grant or award A | +200,000 | – | 244,720 | Form 4 |
| 2025-03-21 | Panchal NikulChief Pharmacy Officer | Grant or award A | +90,000 | – | 90,000 | Form 4 |
| 2025-03-21 | Norton BrianChief Executive Officer | Grant or award A | +9,000,000 | – | 9,044,720 | Form 4 |
| 2025-03-21 | Anderson Donald WilliamDirector | Grant or award A | +200,000 | – | 244,720 | Form 4 |
| 2025-03-21 | Patel PrashantDirector, Chief Strategy Officer | Grant or award A | +1,882,247 | – | 4,118,247 | Form 4 |
| 2025-03-21 | Patel PrashantDirector, Chief Strategy Officer | Grant or award A | +1,500,000 | – | 1,500,000 | Form 4 |
| 2025-03-21 | Patel PrashantDirector, Chief Strategy Officer | Grant or award A | +700,000 | – | 700,000 | Form 4 |
| 2025-03-21 | Ajjarapu Surendra KDirector | Grant or award A | +2,882,247 | – | 1,822,247 | Form 4 |
| 2025-03-21 | Ajjarapu Surendra KDirector | Grant or award A | +600,000 | – | 4,463,200 | Form 4 |
| 2025-03-21 | Ajjarapu Surendra KDirector | Grant or award A | +600,000 | – | 3,100,000 | Form 4 |
| 2025-03-21 | Syed SajidDirector | Grant or award A | +200,000 | – | 244,720 | Form 4 |
| 2025-03-21 | Pirani ShafaatChief Clinical Officer | Grant or award A | +35,000 | – | 102,080 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.